Belimumab corticosteroid-sparing treatment in systemic lupus erythematosus: a real-life observational study (BESST study)
Data about the impact of Belimumab on corticosteroid sparing in real life are scarce. To assess the corticosteroid-sparing effect among patients with systemic lupus erythematosus (SLE) treated with Belimumab in real-life settings. Multicentric observational retrospective study including patients wit...
Gespeichert in:
| Veröffentlicht in: | Rheumatology international 2024-11, Vol.44 (11), p.2465-2471 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2471 |
|---|---|
| container_issue | 11 |
| container_start_page | 2465 |
| container_title | Rheumatology international |
| container_volume | 44 |
| creator | Jaïs, Marie Roblot, Pascal Maillot, François Hamidou, Mohamed Enfrein, Antoine Lescoat, Alain Puyade, Mathieu Martin, Mickaël Perier, Amandine |
| description | Data about the impact of Belimumab on corticosteroid sparing in real life are scarce. To assess the corticosteroid-sparing effect among patients with systemic lupus erythematosus (SLE) treated with Belimumab in real-life settings. Multicentric observational retrospective study including patients with SLE and having received Belimumab for at least 6 months between 2011 and 2020, in eight French hospitals. “Low dose” referred to patients receiving up to 7.5 mg of prednisone a day and “Very low dose” to those receiving strictly ≤ 5 mg prednisone a day The primary endpoint was the reduction of daily prednisone dose after six months of Belimumab. The secondary endpoint was a change in the proportion of patients with low or very low dose of prednisone as well as those without prednisone during the Belimumab course. Censoring occurred for patients who stopped Belimumab. Bivariate analyses were performed using the Wilcoxon signed-rank test. The threshold for statistical significance was set at
p
|
| doi_str_mv | 10.1007/s00296-024-05589-2 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3049719055</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3049719055</sourcerecordid><originalsourceid>FETCH-LOGICAL-c326t-3febf58da0af1aa7fa6fd440171b2fd02e9f0c3cf75637858e22bfb59ba60ff43</originalsourceid><addsrcrecordid>eNp9kctu0DAQRSNERUvhB1ggS2zKwnRsJ3bCjlblIVXqokViZznJGFwlcfADKX-PS8pDLLqyLZ-5Y8-pqhcM3jAAdRoBeCcp8JpC07Qd5Y-qI1YLRZmEL4__2R9WT2O8BWBKSnhSHYpWtkq0zVG1neHk5jybngw-JDf4mDB4N9K4muCWryQFNGnGJRG3kLiV69kNZMprjgTDlr7hbJKPOb4lhhR2opOzSHwfMfwwyfnFTCSmPG7k5Ozi-vpmP7x-Vh1YM0V8fr8eV5_fX9ycf6SXVx8-nb-7pIPgMlFhsbdNOxowlhmjrJF2rOvyFdZzOwLHzsIgBqsaKVTbtMh5b_um640Ea2txXJ3suWvw3zPGpGcXB5wms6DPUQuoO8W6MsGCvvoPvfU5lPcXikHXcAlCFYrv1BB8jAGtXoObTdg0A30nRu9idBGjf4nRvBS9vI_O_Yzjn5LfJgogdiCud2PH8Lf3A7E_Adjsm7I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3109526037</pqid></control><display><type>article</type><title>Belimumab corticosteroid-sparing treatment in systemic lupus erythematosus: a real-life observational study (BESST study)</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Jaïs, Marie ; Roblot, Pascal ; Maillot, François ; Hamidou, Mohamed ; Enfrein, Antoine ; Lescoat, Alain ; Puyade, Mathieu ; Martin, Mickaël ; Perier, Amandine</creator><creatorcontrib>Jaïs, Marie ; Roblot, Pascal ; Maillot, François ; Hamidou, Mohamed ; Enfrein, Antoine ; Lescoat, Alain ; Puyade, Mathieu ; Martin, Mickaël ; Perier, Amandine</creatorcontrib><description>Data about the impact of Belimumab on corticosteroid sparing in real life are scarce. To assess the corticosteroid-sparing effect among patients with systemic lupus erythematosus (SLE) treated with Belimumab in real-life settings. Multicentric observational retrospective study including patients with SLE and having received Belimumab for at least 6 months between 2011 and 2020, in eight French hospitals. “Low dose” referred to patients receiving up to 7.5 mg of prednisone a day and “Very low dose” to those receiving strictly ≤ 5 mg prednisone a day The primary endpoint was the reduction of daily prednisone dose after six months of Belimumab. The secondary endpoint was a change in the proportion of patients with low or very low dose of prednisone as well as those without prednisone during the Belimumab course. Censoring occurred for patients who stopped Belimumab. Bivariate analyses were performed using the Wilcoxon signed-rank test. The threshold for statistical significance was set at
p
< 0.05. Thirty patients were included. All were female with a median age of 38 years. A significant reduction in prednisone dose was observed at month 6 (10 [7–20] vs 6.75 [2–9] mg,
p
< 0.0001), continued until month 12 (10 [7–20] mg vs 5 [0–7.12] mg,
p
< 0.001) and was sustained until month 24. The proportion of patients with very low dose of prednisone and those without prednisone progressively increased during the Belimumab course. Introducing Belimumab in patients with SLE, in real-life conditions, is associated with early and sustained corticosteroid-sparing effect.</description><identifier>ISSN: 1437-160X</identifier><identifier>ISSN: 0172-8172</identifier><identifier>EISSN: 1437-160X</identifier><identifier>DOI: 10.1007/s00296-024-05589-2</identifier><identifier>PMID: 38687385</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Antibodies, Monoclonal, Humanized - therapeutic use ; Drug Tapering ; Female ; Glucocorticoids - administration & dosage ; Glucocorticoids - therapeutic use ; Humans ; Immunosuppressive Agents - therapeutic use ; Lupus ; Lupus Erythematosus, Systemic - drug therapy ; Medicine ; Medicine & Public Health ; Middle Aged ; Monoclonal antibodies ; Observational Research ; Prednisone - administration & dosage ; Prednisone - therapeutic use ; Retrospective Studies ; Rheumatology ; Steroids ; Treatment Outcome</subject><ispartof>Rheumatology international, 2024-11, Vol.44 (11), p.2465-2471</ispartof><rights>The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c326t-3febf58da0af1aa7fa6fd440171b2fd02e9f0c3cf75637858e22bfb59ba60ff43</cites><orcidid>0000-0002-3826-4584</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00296-024-05589-2$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00296-024-05589-2$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38687385$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jaïs, Marie</creatorcontrib><creatorcontrib>Roblot, Pascal</creatorcontrib><creatorcontrib>Maillot, François</creatorcontrib><creatorcontrib>Hamidou, Mohamed</creatorcontrib><creatorcontrib>Enfrein, Antoine</creatorcontrib><creatorcontrib>Lescoat, Alain</creatorcontrib><creatorcontrib>Puyade, Mathieu</creatorcontrib><creatorcontrib>Martin, Mickaël</creatorcontrib><creatorcontrib>Perier, Amandine</creatorcontrib><title>Belimumab corticosteroid-sparing treatment in systemic lupus erythematosus: a real-life observational study (BESST study)</title><title>Rheumatology international</title><addtitle>Rheumatol Int</addtitle><addtitle>Rheumatol Int</addtitle><description>Data about the impact of Belimumab on corticosteroid sparing in real life are scarce. To assess the corticosteroid-sparing effect among patients with systemic lupus erythematosus (SLE) treated with Belimumab in real-life settings. Multicentric observational retrospective study including patients with SLE and having received Belimumab for at least 6 months between 2011 and 2020, in eight French hospitals. “Low dose” referred to patients receiving up to 7.5 mg of prednisone a day and “Very low dose” to those receiving strictly ≤ 5 mg prednisone a day The primary endpoint was the reduction of daily prednisone dose after six months of Belimumab. The secondary endpoint was a change in the proportion of patients with low or very low dose of prednisone as well as those without prednisone during the Belimumab course. Censoring occurred for patients who stopped Belimumab. Bivariate analyses were performed using the Wilcoxon signed-rank test. The threshold for statistical significance was set at
p
< 0.05. Thirty patients were included. All were female with a median age of 38 years. A significant reduction in prednisone dose was observed at month 6 (10 [7–20] vs 6.75 [2–9] mg,
p
< 0.0001), continued until month 12 (10 [7–20] mg vs 5 [0–7.12] mg,
p
< 0.001) and was sustained until month 24. The proportion of patients with very low dose of prednisone and those without prednisone progressively increased during the Belimumab course. Introducing Belimumab in patients with SLE, in real-life conditions, is associated with early and sustained corticosteroid-sparing effect.</description><subject>Adult</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Drug Tapering</subject><subject>Female</subject><subject>Glucocorticoids - administration & dosage</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Lupus</subject><subject>Lupus Erythematosus, Systemic - drug therapy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Observational Research</subject><subject>Prednisone - administration & dosage</subject><subject>Prednisone - therapeutic use</subject><subject>Retrospective Studies</subject><subject>Rheumatology</subject><subject>Steroids</subject><subject>Treatment Outcome</subject><issn>1437-160X</issn><issn>0172-8172</issn><issn>1437-160X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kctu0DAQRSNERUvhB1ggS2zKwnRsJ3bCjlblIVXqokViZznJGFwlcfADKX-PS8pDLLqyLZ-5Y8-pqhcM3jAAdRoBeCcp8JpC07Qd5Y-qI1YLRZmEL4__2R9WT2O8BWBKSnhSHYpWtkq0zVG1neHk5jybngw-JDf4mDB4N9K4muCWryQFNGnGJRG3kLiV69kNZMprjgTDlr7hbJKPOb4lhhR2opOzSHwfMfwwyfnFTCSmPG7k5Ozi-vpmP7x-Vh1YM0V8fr8eV5_fX9ycf6SXVx8-nb-7pIPgMlFhsbdNOxowlhmjrJF2rOvyFdZzOwLHzsIgBqsaKVTbtMh5b_um640Ea2txXJ3suWvw3zPGpGcXB5wms6DPUQuoO8W6MsGCvvoPvfU5lPcXikHXcAlCFYrv1BB8jAGtXoObTdg0A30nRu9idBGjf4nRvBS9vI_O_Yzjn5LfJgogdiCud2PH8Lf3A7E_Adjsm7I</recordid><startdate>20241101</startdate><enddate>20241101</enddate><creator>Jaïs, Marie</creator><creator>Roblot, Pascal</creator><creator>Maillot, François</creator><creator>Hamidou, Mohamed</creator><creator>Enfrein, Antoine</creator><creator>Lescoat, Alain</creator><creator>Puyade, Mathieu</creator><creator>Martin, Mickaël</creator><creator>Perier, Amandine</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3826-4584</orcidid></search><sort><creationdate>20241101</creationdate><title>Belimumab corticosteroid-sparing treatment in systemic lupus erythematosus: a real-life observational study (BESST study)</title><author>Jaïs, Marie ; Roblot, Pascal ; Maillot, François ; Hamidou, Mohamed ; Enfrein, Antoine ; Lescoat, Alain ; Puyade, Mathieu ; Martin, Mickaël ; Perier, Amandine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c326t-3febf58da0af1aa7fa6fd440171b2fd02e9f0c3cf75637858e22bfb59ba60ff43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Drug Tapering</topic><topic>Female</topic><topic>Glucocorticoids - administration & dosage</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Lupus</topic><topic>Lupus Erythematosus, Systemic - drug therapy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Observational Research</topic><topic>Prednisone - administration & dosage</topic><topic>Prednisone - therapeutic use</topic><topic>Retrospective Studies</topic><topic>Rheumatology</topic><topic>Steroids</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jaïs, Marie</creatorcontrib><creatorcontrib>Roblot, Pascal</creatorcontrib><creatorcontrib>Maillot, François</creatorcontrib><creatorcontrib>Hamidou, Mohamed</creatorcontrib><creatorcontrib>Enfrein, Antoine</creatorcontrib><creatorcontrib>Lescoat, Alain</creatorcontrib><creatorcontrib>Puyade, Mathieu</creatorcontrib><creatorcontrib>Martin, Mickaël</creatorcontrib><creatorcontrib>Perier, Amandine</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Rheumatology international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jaïs, Marie</au><au>Roblot, Pascal</au><au>Maillot, François</au><au>Hamidou, Mohamed</au><au>Enfrein, Antoine</au><au>Lescoat, Alain</au><au>Puyade, Mathieu</au><au>Martin, Mickaël</au><au>Perier, Amandine</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Belimumab corticosteroid-sparing treatment in systemic lupus erythematosus: a real-life observational study (BESST study)</atitle><jtitle>Rheumatology international</jtitle><stitle>Rheumatol Int</stitle><addtitle>Rheumatol Int</addtitle><date>2024-11-01</date><risdate>2024</risdate><volume>44</volume><issue>11</issue><spage>2465</spage><epage>2471</epage><pages>2465-2471</pages><issn>1437-160X</issn><issn>0172-8172</issn><eissn>1437-160X</eissn><abstract>Data about the impact of Belimumab on corticosteroid sparing in real life are scarce. To assess the corticosteroid-sparing effect among patients with systemic lupus erythematosus (SLE) treated with Belimumab in real-life settings. Multicentric observational retrospective study including patients with SLE and having received Belimumab for at least 6 months between 2011 and 2020, in eight French hospitals. “Low dose” referred to patients receiving up to 7.5 mg of prednisone a day and “Very low dose” to those receiving strictly ≤ 5 mg prednisone a day The primary endpoint was the reduction of daily prednisone dose after six months of Belimumab. The secondary endpoint was a change in the proportion of patients with low or very low dose of prednisone as well as those without prednisone during the Belimumab course. Censoring occurred for patients who stopped Belimumab. Bivariate analyses were performed using the Wilcoxon signed-rank test. The threshold for statistical significance was set at
p
< 0.05. Thirty patients were included. All were female with a median age of 38 years. A significant reduction in prednisone dose was observed at month 6 (10 [7–20] vs 6.75 [2–9] mg,
p
< 0.0001), continued until month 12 (10 [7–20] mg vs 5 [0–7.12] mg,
p
< 0.001) and was sustained until month 24. The proportion of patients with very low dose of prednisone and those without prednisone progressively increased during the Belimumab course. Introducing Belimumab in patients with SLE, in real-life conditions, is associated with early and sustained corticosteroid-sparing effect.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>38687385</pmid><doi>10.1007/s00296-024-05589-2</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-3826-4584</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1437-160X |
| ispartof | Rheumatology international, 2024-11, Vol.44 (11), p.2465-2471 |
| issn | 1437-160X 0172-8172 1437-160X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3049719055 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Antibodies, Monoclonal, Humanized - therapeutic use Drug Tapering Female Glucocorticoids - administration & dosage Glucocorticoids - therapeutic use Humans Immunosuppressive Agents - therapeutic use Lupus Lupus Erythematosus, Systemic - drug therapy Medicine Medicine & Public Health Middle Aged Monoclonal antibodies Observational Research Prednisone - administration & dosage Prednisone - therapeutic use Retrospective Studies Rheumatology Steroids Treatment Outcome |
| title | Belimumab corticosteroid-sparing treatment in systemic lupus erythematosus: a real-life observational study (BESST study) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T13%3A21%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Belimumab%20corticosteroid-sparing%20treatment%20in%20systemic%20lupus%20erythematosus:%20a%20real-life%20observational%20study%20(BESST%20study)&rft.jtitle=Rheumatology%20international&rft.au=Ja%C3%AFs,%20Marie&rft.date=2024-11-01&rft.volume=44&rft.issue=11&rft.spage=2465&rft.epage=2471&rft.pages=2465-2471&rft.issn=1437-160X&rft.eissn=1437-160X&rft_id=info:doi/10.1007/s00296-024-05589-2&rft_dat=%3Cproquest_cross%3E3049719055%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3109526037&rft_id=info:pmid/38687385&rfr_iscdi=true |